Skip to main content

Advertisement

SpringerLink
Log in

Bone disease in epilepsy

  • Published:
Current Neurology and Neuroscience Reports Aims and scope Submit manuscript

Abstract

Recent literature demonstrates an association between antiepileptic drugs (AEDs) and bone disease. Decreased bone mineral density (BMD) has been found in adults and children receiving both enzyme-inducing AEDs and valproate, which is an enzyme-inhibiting AED. Biochemical abnormalities include hypocalcemia, elevated parathyroid hormone, and elevated markers of bone formation and resorption. Although patients in earlier studies had evidence of decreased vitamin D, low BMD has been found to be independent of abnormal vitamin D chemistries in more recently published studies. Multiple mechanisms have been postulated to explain AED-associated bone disease, but no single mechanism fully explains all the abnormalities seen. Therapies are available for bone disease. However, few studies have evaluated the effects of treatment in bone disease associated with AEDs.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Kruse R: Osteopathien bei antiepileptischer Langzeittherapie. Monatasschr Kinderheilkd 1968, 116:378–381.

    CAS  Google Scholar 

  2. Dent CE, Richens A, Rowe DF, et al.: Osteomalacia with longterm anticonvulsant therapy in epilepsy. BMJ 1970, 4:69–72.

    PubMed  CAS  Google Scholar 

  3. Richens A, Rowe DF: Disturbance of calcium metabolism by anticonvulsant drugs. BMJ 1970, 4:73–76.

    PubMed  CAS  Google Scholar 

  4. Hunter J, Maxwell JD, Stewart DA, et al.: Altered calcium metabolism in epileptic children on anticonvulsants. BMJ 1971, 4:202–204.

    PubMed  CAS  Google Scholar 

  5. Hoikka V, Savolainen K, Esko M, et al.: Osteomalacia in institutionalized epileptic patients on long-term anticonvulsant therapy. Acta Neurol Scand 1981, 64:122–131.

    Article  PubMed  CAS  Google Scholar 

  6. Chung S, Ahn C: Effects of anti-epileptic drug therapy on bone mineral density in ambulatory epileptic children. Brain Dev 1994, 16:382–385.

    Article  PubMed  CAS  Google Scholar 

  7. Valimaki MJ, Tiihonen M, Laitinen K, et al.: Bone mineral density measured by dual-energy X-ray absorptiometry and novel markers of bone formation and resorption in patients on anti-epileptic drugs. J Bone Mineral Res 1994, 9:631–637.

    Article  CAS  Google Scholar 

  8. Gough H, Goggin T, Bissessar A, et al.: A comparative study of the relative influence of different anticonvulsant drugs, UV exposure and diet on vitamin D and calcium metabolism in outpatients with epilepsy. Q J Med 1986, 230:569–577.

    Google Scholar 

  9. Sato Y, Kondo I, Ishida S, et al.: Decreased bone mass and increased bone turnover with valproate therapy in adults with epilepsy. Neurology 2001, 57:445–449. Valproate therapy was associated with reduced BMD, elevated calcium, and elevated markers of bone formation and resorption. Phenytoin therapy was associated with reduced BMD, reduced calcium, and elevated markers of bone formation and resorption.

    PubMed  CAS  Google Scholar 

  10. Hahn TJ, Hendin BA, Scharp CR: Effect of chronic anticonvulsant therapy on serum 25-hydroxycalciferol levels in adults. N Engl J Med 1972, 287:900–904.

    Article  PubMed  CAS  Google Scholar 

  11. Bouillon R, Reynaert J, Claes JH, et al.: The effect of anticonvulsant therapy on serum levels of 25-hydroxyvitamin D, calcium, and parathyroid hormone. J Clin Endocrinol Metab 1975, 41:1130.

    Article  PubMed  CAS  Google Scholar 

  12. Weinstein RS, Bryce GF, Sappington LJ, et al.: Decreased serum ionized calcium and normal vitamin D metabolite levels with anticonvulsant drug treatment. J Clin Endocrinol Metab 1984, 58:1003–1009.

    PubMed  CAS  Google Scholar 

  13. Andress DL, Ozuna J, Tirschwell D, et al.: Antiepileptic druginduced bone loss in young male patients who have seizures. Arch Neurol 2002, 59:781–786. Men aged 25 to 54 years had significantly decreased BMD in absence of vitamin D deficiency. These findings were more significant in younger men and those on the drug for longer periods of time. Ongoing bone loss was found in younger men (aged 25 to 44 years) over a mean period of 19 months.

    Article  PubMed  Google Scholar 

  14. Farhat G, Yamout B, Mikati MA, et al.: Effect of antiepileptic drugs on bone density in ambulatory patients. Neurology 2002, 58:1348–1353. Adults and children/adolescents on AED therapy for at least 6 months had decreased BMD. Although low 25-hydroxyvitamin D levels were decreased in over 50% of the patients, this did not correlate with low BMD. Patients on enzyme-inducing AEDs had lower BMD than those on noninducers.

    PubMed  CAS  Google Scholar 

  15. Verrotti A, Greco R, Morgese G, et al.: Increased bone turnover in epileptic patients treated with carbamazepine. Ann Neurol 2000, 47:385–388. Higher values of markers of bone formation and bone resorption were found in 12 patients with epilepsy treated with carbamazepine for 1 year when compared with sex- and aged-matched controls.

    Article  PubMed  CAS  Google Scholar 

  16. Verrotti A, Greco R, Latini G, et al.: Increased bone turnover in prepubertal, pubertal, and postpubertal patients receiving carbamazepine. Epilepsia 2002, 43:1488–1492. After 2 years of treatment with carbamazepine, higher values of markers of bone formation and bone resorption were found in patients with epilepsy when compared with control subjects. These findings were independent of abnormalities of vitamin D metabolism and pubertal stage.

    Article  PubMed  CAS  Google Scholar 

  17. Nilsson OS, Lindholm TS, Elmstedt E, et al.: Fracture incidence and bone disease in epileptics receiving long-term anticonvulsant drug treatment. Arch Orthop Trauma Surg 1986, 105:146–149.

    Article  PubMed  CAS  Google Scholar 

  18. Cummings SR, Nevitt MC, Browner WS, et al.: Risk factors for hip fracture in white women. Study of Osteoporotic Fractures Research Group. N Engl J Med 1995, 332:767–773.

    Article  PubMed  CAS  Google Scholar 

  19. Jaglal SB, Kreiger N, Darlington GA: Lifetime occupational physical activity and risk of hip fracture in women. Ann Epidemiol 1995, 5:321–324.

    Article  PubMed  CAS  Google Scholar 

  20. Desai KB, Ribbans WJ, Taylor GJ: Incidence of five common fractures in an institutionalized epileptic population. Injury 1996, 27:97–100.

    Article  PubMed  CAS  Google Scholar 

  21. Vestergaard P, Tigaran S, Rejnmark L, et al.: Fracture risk is increased in epilepsy. Acta Neurol Scand 1999, 99:269–275.

    Article  PubMed  CAS  Google Scholar 

  22. Espallargues M, Sampietro-Colom L, Estrada MD, et al.: Identifying bone-mass-related risk factors for fracture to guide bone densitometry measurements: a systematic review of the literature. Osteoporosis Int 2001, 12:811–822.

    Article  CAS  Google Scholar 

  23. Pack AM, Olarte L, Morrell M, et al.: Bone mineral density in an outpatient population receiving enzyme inducing antiepileptic drugs. Epilepsy Behav 2003, 4:169–174.

    Article  PubMed  Google Scholar 

  24. Marshall D, Johnell O, Wedel H: Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ 1996, 312:1254–1259.

    PubMed  CAS  Google Scholar 

  25. Stephen LJ, McLellan AR, Harrison JH, et al.: Bone density and epileptic drugs: a case controlled study. Seizure 1999, 8:339–342.

    Article  PubMed  CAS  Google Scholar 

  26. Voudris K, Moustaki M, Zeis PM, et al.: Alkaline phosphatase and its isoenzyme activity for the evaluation of bone metabolism in children anticonvulsant monotherapy. Seizure 2002, 11:377–380.

    Article  PubMed  Google Scholar 

  27. Altay EB, Serdaroglu A, Tumer L, et al.: Evaluation of bone mineral metabolism in children receiving carbamazepine and valproic acid. J Pediatr Endocrinol Metab 2000, 13:933–939.

    Google Scholar 

  28. Tsukahara H, Kimura K, Todoroki Y, et al.: Bone mineral status in ambulatory pediatric patients on long-term anti-epileptic drug therapy. Pediatr Int 2002, 44:247–253. Children on long-term AED treatment had decreased BMD relative to control subjects. There were reduced markers of bone turnover, including reduced markers of bone formation and resorption, in children on AEDs.

    Article  PubMed  CAS  Google Scholar 

  29. Guo CY, Rone GM, Atkinson SA: Long-term valproate and lamotrigine treatment may be markers for reduced growth and bone mass in children with epilepsy. Epilepsia 2001, 42:1141–1147. Long-term valproate and lamotrigine therapy were associated with short stature, low BMD, and reduced bone formation. These findings were most evident in those with reduced physical exercise and those on a combination of valproate and lamotrigine.

    Article  PubMed  CAS  Google Scholar 

  30. Perucca E: Clinical implications of hepatic microsomal enzyme induction by anti-epileptic drugs. Pharmacol Ther 1987, 33:130–144.

    Article  Google Scholar 

  31. Koch HV, Kratf D, von Herrath D: Influence of diphenylhydantoin and Phenobarbital on intestinal calcium transport in the rat. Epilepsia 1972, 13:829–841.

    PubMed  CAS  Google Scholar 

  32. Takahashi A, Ondera K, Shinoda H, et al.: Phenytoin and its metabolite, 5-(4-hydroxyphenyl)-5-phenylhydantoin, show bone resorption in cultured neonatal mouse calvaria. Jpn J Pharmacol 2000, 82:82–84.

    Article  PubMed  CAS  Google Scholar 

  33. Feldcamp J, Becker A, Witte OW, et al.: Long-term anticonvulsant therapy leads to low bone mineral density—evidence for direct drug effects of phenytoin and carbamazepine on human osteoblast-like cells. Exp Clin Endocrinol Diabetes 2000, 108:37–43.

    Google Scholar 

  34. Braam LA, Knapen MH, Geusens P: Vitamin K1 supplementation retards bone loss in postmenopausal women between 50 and 60 years of age. Calcif Tissue Int 2003, 73:21–26.

    Article  PubMed  CAS  Google Scholar 

  35. Ondera K, Takahashi A, Sakurada S, et al.: Effects of phenytoin and/or vitamin K2 (menatetrenone) on bone mineral density in the tibiae of growing rats. Life Sci 2002, 70:1533–1542.

    Article  Google Scholar 

  36. Vernillo AT, Rifkin BR, Hauschka PV: Phenytoin affects osteoblastic secretion from osteoblastic rat osteosarcoma 17/2.8 cells in culture. Bone 1990, 11:309–312.

    Article  PubMed  CAS  Google Scholar 

  37. Hahn TJ, Hendin BA, Scharp CR, et al.: Serum 25-hydroxy calciferol levels and bone mass in children on chronic anti-epileptic therapy. N Engl J Med 1975, 292:550–554.

    Article  CAS  Google Scholar 

  38. Collins N, Maher J, Cole M, et al.: A prospective study to evaluate the dose of vitamin D required to correct low 25-hydroxyvitamin D levels, calcium, and alkaline phosphatase in patients at risk of developing antiepileptic drug-induced osteomalacia. Q J Med 1991, 78:113–122.

    PubMed  CAS  Google Scholar 

  39. Pedrera JD, Canal ML, Carvajal J, et al.: Influence of vitamin D administration on bone ultrasound measurements in patients on anticonvulsant therapy. Eur J Clin Invest 2000, 30:895–899.

    Article  PubMed  CAS  Google Scholar 

  40. Delmas PD: Treatment of postmenopausal osteoporosis. Lancet 2002, 359:2018–2026.

    Article  PubMed  CAS  Google Scholar 

  41. Writing group for the Women’s Health Initiative Investigators: Risks and benefits of estrogen plus progesterone in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA 2002, 288:366–368.

    Article  Google Scholar 

  42. Harden CL, Pulver MC, Ravdin L, Javobs AR: The effect of menopause and perimenopause on the course of epilepsy. Epilepsia 1999, 40:1402–1407.

    Article  PubMed  CAS  Google Scholar 

  43. Delmas PD, Bjarnason NH, Mitlak et al.: Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N Engl J Med 1997, 337:1641–1647.

    Article  PubMed  CAS  Google Scholar 

  44. Ettinger B, Black DM, Mitlak et al.: Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. JAMA 1999, 282:637–645.

    Article  PubMed  CAS  Google Scholar 

  45. Chestnut CH, Silverman S, Andriano K, et al.: A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. Am J Med 2000, 109:267–276.

    Article  Google Scholar 

  46. Valmadrid C, Voorhees C, Litt B, et al.: Practice parameters of neurologists regarding bone and mineral effects of antiepileptic drug therapy. Arch Neurol 2001, 58:1369–1374. In a survey of adult and pediatric neurologists, it was found that few evaluated AED-treated patients for bone disease, and when there was evidence of bone disease they often did not intervene or refer for treatment. In addition, approximately 50% of pediatric and adult neurologists recommended prophylactic calcium and vitamin D. Neurologists need to aware of reported effects of AEDs on bone.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. New York Neurological Institute, 710 West 168th Street, 10032, New York, NY, USA

    Alison M. Pack MD

Authors
  1. Alison M. Pack MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Pack, A.M. Bone disease in epilepsy. Curr Neurol Neurosci Rep 4, 329–334 (2004). https://doi.org/10.1007/s11910-004-0060-2

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11910-004-0060-2

Keywords

Search

Navigation